NO981799L - Farmas÷ytiske blandinger av levo-enantiomere av medetomidinderivater og deres anvendelse - Google Patents

Farmas÷ytiske blandinger av levo-enantiomere av medetomidinderivater og deres anvendelse

Info

Publication number
NO981799L
NO981799L NO981799A NO981799A NO981799L NO 981799 L NO981799 L NO 981799L NO 981799 A NO981799 A NO 981799A NO 981799 A NO981799 A NO 981799A NO 981799 L NO981799 L NO 981799L
Authority
NO
Norway
Prior art keywords
pct
receptors
adrenergic alpha
medetomidine
levo
Prior art date
Application number
NO981799A
Other languages
English (en)
Norwegian (no)
Other versions
NO981799D0 (no
Inventor
Karl E O Kerman
Christian Jansson
Jyrki Kukkonen
Juha-Matti Savola
Siegfried Wurster
Victor Cockcroft
Original Assignee
Orion Corp
Karl E O Kerman
Christian Jansson
Jyrki Kukkonen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp, Karl E O Kerman, Christian Jansson, Jyrki Kukkonen filed Critical Orion Corp
Publication of NO981799D0 publication Critical patent/NO981799D0/no
Publication of NO981799L publication Critical patent/NO981799L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Resins (AREA)
NO981799A 1995-10-23 1998-04-22 Farmas÷ytiske blandinger av levo-enantiomere av medetomidinderivater og deres anvendelse NO981799L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521680.0A GB9521680D0 (en) 1995-10-23 1995-10-23 New use of imidazole derivatives
PCT/FI1996/000560 WO1997015302A1 (en) 1995-10-23 1996-10-23 Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use

Publications (2)

Publication Number Publication Date
NO981799D0 NO981799D0 (no) 1998-04-22
NO981799L true NO981799L (no) 1998-04-22

Family

ID=10782758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981799A NO981799L (no) 1995-10-23 1998-04-22 Farmas÷ytiske blandinger av levo-enantiomere av medetomidinderivater og deres anvendelse

Country Status (22)

Country Link
US (1) US5994384A (ru)
EP (1) EP0858338B1 (ru)
JP (1) JP2000503298A (ru)
KR (1) KR19990067008A (ru)
CN (1) CN1200035A (ru)
AT (1) ATE218340T1 (ru)
AU (1) AU707728B2 (ru)
BG (1) BG102396A (ru)
CA (1) CA2232336A1 (ru)
CZ (1) CZ120498A3 (ru)
DE (1) DE69621633T2 (ru)
EE (1) EE9800131A (ru)
ES (1) ES2178717T3 (ru)
GB (1) GB9521680D0 (ru)
HU (1) HUP9900027A3 (ru)
IL (1) IL123999A (ru)
NO (1) NO981799L (ru)
NZ (1) NZ320289A (ru)
PL (1) PL326562A1 (ru)
RU (1) RU2193404C2 (ru)
SK (1) SK48698A3 (ru)
WO (1) WO1997015302A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
AU5331200A (en) * 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
JP2009524616A (ja) 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ疾患のための４−イミダゾール誘導体の使用
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
WO2013078151A1 (en) * 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
WO2015011177A1 (en) * 2013-07-24 2015-01-29 I-Tech Ab Use of the enantiomer levomedetomidine as inhibitor for marine biofouling of surfaces
WO2015054059A2 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CN105764494A (zh) 2013-10-07 2016-07-13 帝国制药美国公司 右旋美托咪啶经皮递送装置及其使用方法
EP3054930B1 (en) 2013-10-07 2020-12-02 Teikoku Pharma USA, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
EP3054934B1 (en) * 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
CN106442765A (zh) * 2016-08-31 2017-02-22 辰欣药业股份有限公司 一种盐酸右美托咪定粗品中异构体的检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
AU671071B2 (en) * 1990-08-30 1996-08-15 State of Oregon, acting by and through The Oregon State Board of Higher Education, acting for and on behalf of The Oregon Health Sciences University, Portland, Oregon, and The University of Oregon, Eugene, Oregon, Johnson Hall, Substituted amidines having high binding to the sigma receptor and the use thereof
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9310965D0 (en) * 1993-05-27 1993-07-14 Ucb Sa 2-hydroxy-3-(1h-imidazol-4-yl)alkyl)benzenecarboximidamides

Also Published As

Publication number Publication date
CA2232336A1 (en) 1997-05-01
SK48698A3 (en) 1999-03-12
NO981799D0 (no) 1998-04-22
ES2178717T3 (es) 2003-01-01
DE69621633T2 (de) 2003-02-06
CN1200035A (zh) 1998-11-25
JP2000503298A (ja) 2000-03-21
US5994384A (en) 1999-11-30
KR19990067008A (ko) 1999-08-16
RU2193404C2 (ru) 2002-11-27
AU707728B2 (en) 1999-07-15
DE69621633D1 (de) 2002-07-11
ATE218340T1 (de) 2002-06-15
BG102396A (en) 1999-01-29
CZ120498A3 (cs) 1998-09-16
GB9521680D0 (en) 1996-01-03
WO1997015302A1 (en) 1997-05-01
HUP9900027A2 (hu) 1999-04-28
EE9800131A (et) 1998-10-15
PL326562A1 (en) 1998-09-28
AU7301996A (en) 1997-05-15
IL123999A (en) 2002-09-12
NZ320289A (en) 1999-08-30
EP0858338A1 (en) 1998-08-19
EP0858338B1 (en) 2002-06-05
HUP9900027A3 (en) 1999-11-29

Similar Documents

Publication Publication Date Title
NO981799D0 (no) Farmas÷ytiske blandinger av levo-enantiomere av medetomidinderivater og deres anvendelse
AU2002234134A1 (en) 3-substituted oxindole beta 3 agonists
GR3021804T3 (en) Indole derivatives as 5-h1-like agonists for use in migraine
AU2506197A (en) Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity
ES2121193T3 (es) Derivados de bencimidazoles.
AU2002318206A1 (en) 3-substituted oxindole beta-3 agonists
NO952229L (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
FI935960A (fi) Foerfarande foer framstaellning av papper
EG21209A (en) Indole derivatives
ATE297925T1 (de) 3-substituierte oxindol beta 3 agonisten
ES2110225T3 (es) Derivados antisicoticos de indazol.
GB9210400D0 (en) Therapeutic agents
DE69633943D1 (de) Morphine derivate mit analgetischen eigenschaften
CA2254116A1 (en) Method and composition for the treatment of lipid and glucose metabolism disorders
Jones et al. Characterization of a prostanoid EP3‐receptor in guinea‐pig aorta: partial agonist action of the non‐prostanoid ONO‐AP‐324
DK0804152T3 (da) Lactulose-pastiller
Altenburg et al. Tizanidine Protects Mice against Convulsions Induced by Lidocaine: Involvement of α2‐Adrenoceptors
AU3267097A (en) Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use
Kitamura et al. Effects of nifedipine and Bay K 8644 on contractile activities in single skeletal muscle fibers of the frog
GB9809555D0 (en) Use of neuropeptide Y receptor agonists for treating migraine
MY108739A (en) Imidazole, triazole and tetrazole derivatives